ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1355

14-3-3η:  Useful for More Than the Diagnosis of Rheumatoid Arthritis?

Lisa Zickuhr1, Maryam Pourpaki2, Martha M. Brooks3 and Amy Joseph4, 1Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 2Rheumatology, Advocate Christ Medical Center at Chicago, Oak Lawn, IL, 3Rheumatology, St. Louis VA Medical Center, St. Louis, MO, 4Rheumatology, Veterans Administration Central Office, St. Louis, MO

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: biomarkers and rheumatoid arthritis (RA), Hepatitis C

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Chronic hepatitis C virus (HCV) infection can masquerade as rheumatoid arthritis (RA). Distinguishing between the two is important because treatments differ. 14-3-3η has been explored in RA. When combined with traditional antibodies, high titers of 14-3-3η improve the accuracy of RA diagnosis. The utility of measuring 14-3-3η is not well understood in viral infections, such as HCV. We measure the incidence of 14-3-3η in patients with chronic HCV infection with long-standing arthralgias and compare it to the incidence in patients with long-standing RA to assess its utility in differentiating the two.

Methods: We recruited patients at the VA St. Louis Health Care System in St. Louis, MO, with an established diagnosis of either RA per 2010 ACR/EULAR Classification Criteria for RA or chronic HCV infection (defined as a detectable HCV viral load) with arthralgias of at least three joints. We obtained clinical information from chart review and physical exam at time of enrollment. We measured serum 14-3-3η titers with a quantitative sandwich ELISA (Quest Diagnostics Nichols Institute, San Juan Capistrano, CA), defining presence of 14-3-3η as a serum titer >0.19ng/mL.  Chi-squared analysis compared the incidence of 14-3-3η in the two groups (α = 0.05).

Results:

RA (N = 14)
N (%)

HCV (N=21)
N (%)

Gender
    Female
    Male

2   (14.3%)
12 (85.7%)

1   (4.8%)
20 (95.2%)

Age ± STD (years)

65.1 ± 8.8

63.7 ± 3.5

Ethnicity
    Caucasian
    African American
    Hispanic
    Other (Asian, Native American)

12 (85.7%)
2   (14.3%)
         —
         —

7   (33.3%)
12 (57.1%)
1   (4.8%)
1   (4.8%)

Duration of Joint Disease ± STD (years)

11.9 ± 12.2

18.7 ± 11.1

Number of Joints Involved ± STD

14 ± 5

3.5 ± 0.5

Active Disease, Synovitis at Time of Enrollment

2   (14.3%)

0    (0%)

Treatment
    None
    DMARDs
    Biologics

1   (7.1%)
12 (85.7%)
2   (14.3%)

20 (95.2%)
1   (4.8%)
        —

Serologies

    Rheumatoid Factor (RF)

    Anti-Citrullinated Peptide (CCP)  

7   (50%)

11 (78.6%)

7   (33.3%)

0   (0%)

Presence of 14-3-3 η

2   (14.3%)

1   (4.8%)

Erosions on X-ray

3   (21.4%)

0   (0%)

Both groups had long-standing joint disease of more than ten years. All RA patients met 2010 ACR/EULAR Classification Criteria for RA, and all HCV patients had detectable viral loads. Only two (14.3%) RA patients and 1 (4.8%) HCV patient had elevated 14-3-3η. Chi-square showed no significant association between 14-3-3η positivity and diagnosis of either RA or HCV (X2 = 0.73, p=0.39). Of the two RA patients with elevated 14-3-3η, both (100%) had RF and anti-CCP antibodies, and one (50%) had active disease, with synovitis at time of enrollment and radiographic erosions. The HCV patient with elevated 14-3-3η was RF positive. 

Conclusion: We show a low incidence of 14-3-3η in a cohort of patients with long-standing RA or chronic HCV with arthralgias, lower than what was reported previously. In our cohort, 14-3-3η did not distinguish between joint pain from RA or chronic HCV infection. This suggests it is not useful in patients with long symptom duration. Most of our RA cohort’s disease was controlled on therapy. Therefore, detection of 14-3-3η may be most useful early in the disease course and may be a good biomarker of disease activity. Additional studies correlating 14-3-3η positivity with disease activity and duration are warranted.

 


Disclosure: L. Zickuhr, None; M. Pourpaki, None; M. M. Brooks, None; A. Joseph, None.

To cite this abstract in AMA style:

Zickuhr L, Pourpaki M, Brooks MM, Joseph A. 14-3-3η:  Useful for More Than the Diagnosis of Rheumatoid Arthritis? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/14-3-3%ce%b7-useful-for-more-than-the-diagnosis-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/14-3-3%ce%b7-useful-for-more-than-the-diagnosis-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology